ENDV:
Endovasc Announces U.S. Patent Office Notification for Resorbable Biodegradable
Stent
Business Editors & Health/Medical Writers
BIOWIRE2K
MONTGOMERY, Texas--(BW HealthWire)--Nov. 15, 2001--Endovasc Ltd.
Inc. announced today the U.S. Patent Office (USPTO) has sent the
company notification of allowable claims on the company's
continuation-in-part of its previous stent patent, U.S. Patent
5,980,551 issued Nov. 9, 1999 for a Totally Resorbable Biodegradable
Stent.
"This second patent greatly strengthens our Company's intellectual
property built around this technology," said the inventor and CEO of
Endovasc, Dr. David P. Summers. "We have three prior stent patents
which mention, either in text or in claims, a biodegradable stent with
the earliest citation going back to a 1992 filing date."
The Company's resorbable prosthesis (stent) is a unique concept in
the medical device market. There are no stent products currently on
the market which will totally degrade by natural biological processes
leaving the vessel or organ totally free from any prosthetic remains.
The resorbable prosthesis maintains strength needed to acutely open
and maintain a vessel, duct, tract or organ confirmation and also
precise chronicity controlling the release and delivery of drugs or
biologic agents providing a medicinal therapy.
The multi-billion dollar market for medical devices continues to
grow, with the top three medical device manufacturers reporting
worldwide stent sales during 2000 at over a billion dollars.
About Endovasc Ltd. Inc.
Endovasc Ltd. Inc. is a biopharmaceutical biotech company
pioneering drug delivery technology. The Company's products and
processes, which include Liprostin(TM) (liposome encapsulated PGE-1),
NRA (Nicotine Receptor Agonist, an angiogenic agent), PROSTENT(TM)
stent-coating technology, and a biodegradable resorbable prosthesis
are covered by patents, license and trade secrets for competing in a
multi-billion dollar market.
The foregoing statements are made under the "Safe Harbor" Private
Securities Litigation Reform Act of 1995 and may contain
forward-looking statements that involve risks and uncertainties that
may not be evident at the time of this release. For more information
about Endovasc Ltd. Inc., contact:
--30--AA/ho*
CONTACT: Endovasc Ltd. Inc., Montgomery
New Business Development and Investor Relations:
John (Jack) T. Sorbi, 936/448-2222
Fax: 936/582-2250
jack@endovasc.com
www.endovasc.com
KEYWORD: TEXAS
INDUSTRY KEYWORD: BIOTECHNOLOGY MANUFACTURING MEDICAL
MEDICAL DEVICES PHARMACEUTICAL
SOURCE: Endovasc Ltd. Inc.
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com
Nov-15-2001 12:30 GMT
Symbols:
US;ENDV
Source BW Business Wire
Categories:
MST/R/US/TX MST/I/BTC MST/I/ICS MST/I/MTC MST/I/MTC |
